The Food and Drug Administration currently does not monitor drug prices. As FDA leaders note, the agency's responsibility is for drug safety and efficacy, and besides they do not want to become embroiled in drug pricing controversies. However, monitoring drug pricing can be useful beyond any...

Third party litigation funding (“TPLF”) is controversial. To its detractors, TPLF creates serious ethical and national security risks, and results in defendants paying out large “blackmail settlements” based on marginal (if not wholly) frivolous claims. To its supporters, TPLF helps...